Valbiotis 관리

관리 기준 확인 4/4

Valbiotis CEO는 Sebastien Peltier, Mar2017 에 임명되었습니다 의 임기는 7.67 년입니다. 총 연간 보상은 € 301.00K, 59.8% 로 구성됩니다. 59.8% 급여 및 40.2% 보너스(회사 주식 및 옵션 포함). 는 € 778.57K 가치에 해당하는 회사 주식의 4% 직접 소유합니다. 778.57K. 경영진과 이사회의 평균 재임 기간은 각각 5.8 년과 7.1 년입니다.

주요 정보

Sebastien Peltier

최고 경영자

€301.0k

총 보상

CEO 급여 비율	59.8%
CEO 임기	7.7yrs
CEO 소유권	4.0%
경영진 평균 재임 기간	5.8yrs
이사회 평균 재임 기간	7.1yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Sebastien Peltier 의 보수는 Valbiotis 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-€9m
Mar 31 2024	n/a	n/a	-€8m
Dec 31 2023	€301k	€180k	-€7m
Sep 30 2023	n/a	n/a	-€8m
Jun 30 2023	n/a	n/a	-€9m
Mar 31 2023	n/a	n/a	-€11m
Dec 31 2022	€318k	€180k	-€12m
Sep 30 2022	n/a	n/a	-€11m
Jun 30 2022	n/a	n/a	-€10m
Mar 31 2022	n/a	n/a	-€9m
Dec 31 2021	€259k	€180k	-€9m

보상 대 시장: Sebastien 의 총 보상 ($USD 313.44K ) German 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 471.14K ).

보상과 수익: Sebastien 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Sebastien Peltier (46 yo)

7.7yrs

테뉴어

€301,000

보상

Mr. Sebastien Peltier, Ph D., HDR serves as the Chief Executive Officer of Valbiotis SA and is Co-Founder of Valbiotis. Mr. Peltier has been Member of Management Board of Valbiotis SA from March 7, 2017 an...

리더십 팀

이름	위치	테뉴어	보상	소유권
Sebastien Peltier	Co-Founder	7.7yrs	€301.00k	4% € 778.6k
Sebastien Bessy	COO & Member of the Management Board	3.4yrs	€295.00k	0.035% € 6.8k
Pascal Sirvent	CSO & Member of the Management Board	6.2yrs	€236.00k	0.12% € 23.7k
Murielle Cazaubiel	CMO & Member of the Management Board	5.8yrs	€255.00k	0.0026% € 505.7
Stanislas Sordet	CFO & Member of Management Board	less than a year	데이터 없음	데이터 없음
Charlotte Jezequel	Director of HR & Member of Management Board	1.8yrs	데이터 없음	데이터 없음
Josep Infesta	Head of Global Business Development	5.8yrs	데이터 없음	데이터 없음

5.8yrs

평균 재임 기간

경험이 풍부한 관리: 8JD 의 관리팀은 노련하고 경험 (평균 재직 기간 5.8 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Agnes Tixier	Member of Supervisory Board	5.7yrs	데이터 없음	데이터 없음
Laurent Levy	Chairman of Supervisory Board	7.7yrs	데이터 없음	데이터 없음
Nathalie Boisseau	Member of Scientific & Medical Board	no data	데이터 없음	데이터 없음
Jean-Marie Bard	Member of Scientific & Medical Board	no data	데이터 없음	데이터 없음
Samy Hadjadj	Member of Scientific & Medical Board	no data	데이터 없음	데이터 없음
Thierry Maugard	Member of Scientific & Medical Board	no data	데이터 없음	데이터 없음
Bruno Guigas	Member of Scientific & Medical Board	no data	데이터 없음	데이터 없음
André Marette	Member of Scientific & Medical Board	no data	데이터 없음	데이터 없음
Jean Zetlaoui	Member of Supervisory Board	7.1yrs	데이터 없음	데이터 없음

7.1yrs

평균 재임 기간

경험이 풍부한 이사회: 8JD 의 이사회는 경험(평균 재직 기간 7.1 년)으로 간주됩니다.

Valbiotis 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Valbiotis SA, Annual General Meeting, Jun 25, 2024

Valbiotis Appoints Frédéric PELONG to Board of Directors

Valbiotis Appoints Frédéric PELONG to Board of Directors

No independent directors

Valbiotis Announces Board of Directors Changes

Recent updates

New minor risk - Profitability

New major risk - Share price stability

Valbiotis SA, Annual General Meeting, Jun 25, 2024

Full year 2023 earnings released

New minor risk - Shareholder dilution

New minor risk - Profitability

Valbiotis SA has filed a Follow-on Equity Offering in the amount of €15.000001 million.

Valbiotis SA Presents the Full Results of the Phase II/III REVERSE-IT Study: Impressive Efficacy of TOTUM 63 Against Prediabetes and the Early Stages of Type 2 Diabetes, a First for a Non-drug Active Substance

Valbiotis Announces the Large Success of the REVERSE-IT International Multicentric Phase II/III Clinical Study on TOTUM-63

Forecast breakeven date pushed back to 2025

Full year 2022 earnings released

Valbiotis Announces Positive Results in the Bioavailability and Mode of Action TOTUM--854 Clinical Study, Against High Blood Pressure

Forecast breakeven date pushed back to 2024

Valbiotis SA announced that it has received €9.7 million in funding

Valbiotis SA Presents Additional Positive Results from the HEART Clinical Study on TOTUM•070 for Hypercholesterolemia

First half 2022 earnings released

Valbiotis Appoints Frédéric PELONG to Board of Directors

Valbiotis Appoints Frédéric PELONG to Board of Directors

Valbiotis Announces Completion of Recruitment for the Phase Ii/Iii Reverse-It Clinical Study with Totum•63 Against Prediabetes, in Partnership with Nestlé Health Science

Valbiotis Announces the Major Success of the Phase II Heart Clinical Study the Patented Plant-Based Active Substance Totum•070 Proves Its Efficacy Against Hypercholesterolemia, A Cardiovascular Risk Factor

No independent directors

Valbiotis SA Announces the Positive Results of Its Clinical Study on the Bioavailability and Mode of Action of TOTUM•070, Against Hypercholesterolemia

Full year 2021 earnings: Revenues miss analyst expectations

Valbiotis Announces Board of Directors Changes

Valbiotis SA to Report Fiscal Year 2021 Results on Mar 15, 2022

Valbiotis Announces Approval to Launch the Two Phase II/III Insight and Insight 2 Clinical Studies, the Last Step in the Development of Totum•854 for the Reduction of Blood Pressure

Forecast to breakeven in 2023

Valbiotis Submits to the Competent Authorities the Three Clinical Protocols for TOTUM•854 Indicated in the Reduction of Blood Pressure and Presents its Comprehensive Clinical Development Plan

First half 2021 earnings released

Valbiotis Announces the Publication of the First Scientific Papers on TOTUM•63 in Three International Journals, Elucidating Its Multitarget Mode of Action

Full year 2020 earnings released

Valbiotis SA to Report First Half, 2021 Results on Sep 30, 2021

Valbiotis Selected to Present TOTUM-854 Results on Arterial Hypertension

Valbiotis SA Announces the First Patient’s First Visit in the Phase II HEART Clinical Study on TOTUM-070 and Steps up Its Research Program Against Hypercholesterolemia in 2021

Valbiotis Authorizes to Launch Heart, the Phase II Multi-Center Clinical Study with TOTUM-070, for the Reduction of Blood LDL-Cholesterol Levels

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간